Bristol-Myers Squibb: Sclerosis trials

The registry lists 13 Sclerosis studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 3Phase 2 3Phase 3 6Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesRecruitingNCT07115745Phase 1
• A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple SclerosisTerminatedNCT05064436Phase 1Results posted
• Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying TherapyCompletedNCT05028634Phase 3Results posted
• A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisCompletedNCT02576717Phase 3Results posted
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)CompletedNCT02294058Phase 3Results posted
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisCompletedNCT02047734Phase 3Results posted
• Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis PatientsCompletedNCT01628393Phase 2/3Results posted
• Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung DiseaseTerminatedNCT01559129Phase 2Results posted
• A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisActive, not recruitingNCT06396039Phase 4
• A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their InfantsActive, not recruitingNCT06133049
• Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)TerminatedNCT04140305Phase 3
• Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMSCompletedNCT02797015Phase 1
• A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple SclerosisTerminatedNCT00035529Phase 2